We have measured serum procalcitonin (PCT) concentrations after cardiac surgery in 36 patients allocated to one of three groups: group 1, coronary artery bypass grafting (CABG) with cardiopulmonary bypass (CPB) (n = 12); group 2, CABG without CPB (n = 12); and group 3, valvular surgery with CPB (n = 12). Serum PCT and C-reactive protein (CRP) concentrations were measured before operation, at the end of surgery and daily until postoperative day 8. Serum PCT concentrations increased, irrespective of the type of cardiac surgery, with maximum concentrations on day 1: mean 1.3 (SD 1.8), 1.1 (1.2) and 1.4 (1.2) ng ml-1 in groups 1, 2 and 3, respectively (ns). Serum PCT concentrations remained less than 5 ng ml-1 in all patients. Concentrations returned to normal by day 5 in all groups. To determine the effect of the systemic inflammatory response (SIRS) on serum PCT concentrations, patients were divided post hoc, without considering the type of cardiac surgery, into patients with SIRS (n = 19) and those without SIRS (n = 17). The increase in serum PCT was significantly greater in SIRS (peak PCT 1.79 (1.64) ng ml-1 vs 0.34 (0.32) ng ml-1 in patients without SIRS) (P = 0.005). Samples for PCT and CRP measurements were obtained from 10 other patients with postoperative complications (circulatory failure n = 7; active endocarditis n = 2; septic shock n = 1). In these patients, serum PCT concentrations ranged from 6.2 to 230 ng ml-1. Serum CRP concentrations increased in all patients, with no differences between groups. The postoperative increase in CRP lasted longer than that of PCT. We conclude that SIRS induced by cardiac surgery, with and without CPB, influenced serum PCT concentrations with a moderate and transient postoperative peak on the first day after operation. A postoperative serum PCT concentration of more than 5 ng ml-1 is highly suggestive of a postoperative complication.
Cardiac surgery with cardiopulmonary bypass influences serum PCT concentration with a peak on POD 1. In the presence of fever, PCT is a reliable marker for diagnosis of infection after cardiac surgery, except in patients who previously received antibiotics. PCT was more relevant than CRP for diagnosis of postoperative infection. During a postoperative circulatory failure, a serum PCT concentration >10 ng/mL is highly indicative of a septic shock.
Prevention of splanchnic ischemia during CPB should focus on preservation of high CPB blood flow rather than on high pressure.
Introduction Few cases of arterial thromboembolisms have been reported after novel coronavirus disease 2019 (COVID-19) in case of severe infection or in elderly patients. We report a case of femoral arterial thrombosis in a young patient after nonsevere infection. Case description A common femoral artery thrombosis extended in the first third of superficial and profunda femoral arteries associated with tibial posterior and popliteal artery thrombosis was diagnosed in a 24-year-old man complaining of right lower limb pain for one month. The evolution was good after anticoagulation and antiaggregant treatments and thrombectomy. Etiologic assessment was negative except for nonsevere COVID-19. Discussion COVID-19 accesses host cells via angiotensin-converting enzyme 2 protein, abundant in the lungs, which is also expressed by endothelial cells and is associated with important inflammatory syndrome and coagulopathy, leading to vascular lesions. Thrombosis prevalence is not fully established and seems to be higher in case of major inflammation and in the intensive care unit (ICU). Arterial thromboembolisms are described in many vascular territories, each time in elderly patients, or in case of severe infection. We described a femoral arterial thrombosis in a young patient with negative etiological assessment except nonsevere COVID-19. Treatment consists in anticoagulation and antiaggregant drugs and thrombectomy. Preventing venous thromboembolism treatment is recommended in case of severe infection or in the ICU, but there is no clear recommendation for arterial thromboembolism prevention. This case should lead us to be very careful of the arterial event risk even if the infection is nonsevere and the patient is young.
Decreased gut perfusion has been reported during cardiopulmonary bypass (CPB). Studies of treatments to avoid splanchnic ischaemia during CPB have given conflicting results. We studied 12 rabbits during mild hypothermic non-pulsatile CPB. Tissue blood flow in three different splanchnic areas (gastric, jejunum and ileum) was measured by laser Doppler velocimetry (LDV) before CPB (T0), after steady state (T1), after administration of dopexamine 2 micrograms kg-1 min-1 (T2) and 4 micrograms kg-1 min-1 (T3), and after return to baseline (T4). Splanchnic blood flow decreased during CPB. Dopexamine increased significantly jejunum LDV (100% at T1 to mean 271 (SD 210)% at T2) and ileum LDV (100% at T1 to 187 (112)% at T2). Gastric LDV was not altered by infusion of dopexamine during CPB. This could partly explain the conflicting results on the value of gastric tonometry as an index of splanchnic injury.
Objectif : Rappeler les notions de pharmacologie et de physiopathologie nécessaires à l'utilisation des bêta-bloquants (BB) en médecine périopératoire.Sources : Recherche manuelle et informatisée de la littérature. (mots-clés : anesthesia and beta-blocker, surgery and beta-blocker).Constatations principales : Les BB cardiosélectifs bloquent préférentiellement les bêta-1 récepteurs, induisant une diminution de la fréquence cardiaque et de l'inotropisme, conduisant à la diminution de la consommation d'oxygène myocardique. Les BB non cardiosélectifs bloquent également les bêta-2 récepteurs, induisent une élé-vation des résistances vasculaires périphériques et bronchiques et augmentent les contractions utérines. Cependant, certains BB possèdent des effets vasodilatateurs (carvédilol, céliprolol, labétalol). Les contre-indications des BB résultent logiquement de leurs effets pharmacologiques. Le traitement BB tend à augmenter la densité des bêta-récepteurs membranaires, expliquant les manifestations d'hyperactivité du système nerveux sympathique observées lors de leur sevrage. Depuis la découverte du propranolol en 1964, les BB ont connu des fortunes diverses en anesthésie. Initialement, la sympatholyse partielle qu'ils induisent a été redoutée dans les situations de stress provoquées par les agents anesthésiques et surtout les manipulations chirurgicales. Cependant, les travaux publiés à partir de 1973 ont suggéré un effet hémodynamique protecteur. Conclusion :Les travaux récents ont démontré le caractère bénéfique de la poursuite des traitements BB jusqu'à l'anesthésie à l'exception des manifestations d'intolérance telles que l'hypotension ou la bradycardie sévère.Purpose: To review the pharmacologic and pathophysiologic information necessary to prescribe beta-blockers (BB) in perioperative medicine. Data source: Manual retrieval and electronic research of the literature using MEDLINE (key-words: anesthesia and beta-blocker; surgery and beta-blocker).Data synthesis: Cardioselective BB inhibit preferentially beta-1 receptors, inducing a decrease in heart rate and cardiac inotropism leading to reduction of oxygen myocardial consumption. Non-cardioselective BB inhibit also beta-2 receptors, increasing bronchial and peripheral vascular resistances and uterine contractions. However, some BB are also vasodilators (carvedilol, celiprolol, labetalol). Contraindications to BB result logically from their pharmacological effects. Treatment with BB increases membrane beta-receptor density; this explains sympathetic overactivity observed during weaning of treatment. Since the discovery of propranolol in 1964, the use of BB has been controversial in anesthesia. Formerly, the adverse effects of partial sympatholysis during anesthesia and surgery were feared. However, since 1973, experimental and clinical data have suggested a protective hemodynamic effect.Conclusion: Continued administration of BB up to the time of anesthesia has been encouraged except in patients with signs of intolerance such as hypotension or excessive bradyca...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.